Skip to main content

Advertisement

SpringerLink
Log in

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients

  • Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Introduction

The presence of disseminated tumor cells in the bone marrow of breast cancer patients has proven to be an independent prognostic factor. The aim of this study was to investigate the status of tumor cell dissemination after primary systemic therapy in relation to therapy response.

Methods

Bone marrow aspirates were obtained from 120 patients after completion of primary systemic therapy. Disseminated tumor cells were detected by immunocytochemistry using the APAAP method. Bone marrow status was correlated with clinicopathological factors as well as tumor response to primary systemic therapy.

Results

Sixty out of 120 patients had disseminated tumor cells in their bone marrow aspirates (50%). Response rates were 18% for pathologic complete remission, 52% for partial remission, 28% for no change and 3% for progression. Despite complete remission, 36% of these patients were bone marrow positive. In the partial remission group, the positivity rate was 48%. About 61% of patients with stable disease had disseminated tumor cells in their bone marrow. A trend to higher positivity rates was observed in the poor responder group compared to responders (61% vs. 38%, P = 0.1).

Conclusion

Primary systemic therapy does not completely eradicate disseminated tumor cells in the bone marrow of breast cancer patients. The biological role of persistent disseminated tumor cells needs to be further investigated to optimize current and future therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer. Eight year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100

    PubMed  CAS  Google Scholar 

  2. Fisher B, Bryant J, Wolmark N (1998) Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685

    PubMed  CAS  Google Scholar 

  3. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19(22):4224–4237

    PubMed  Google Scholar 

  4. von Minckwitz G, Raab G, Schütte M et al (2003) Dose-dense versus sequential Adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2–3, N0–2, M0): Primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol 21:43a, (abstr 168)

  5. NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results of the NSABP Protocol B-27. Breast Cancer Res Treat 69:210, (abstr 5) 2001 (updated with personal communication 2002, 2003)

  6. Cunningham JD, Weiss SE, Ahmed S, Bratton JM, Bleiweiss IJ, Tartter PI, Brower ST (1998) The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 16:80–86

    PubMed  CAS  Google Scholar 

  7. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493

    PubMed  CAS  Google Scholar 

  8. Braun S, Rosenberg R, Thorban S et al (2001) Implications of occult metastatic cells for systemic cancer treatment in patients with breast of gastrointestinal cancer. Semin Surg Oncol 20(4):334–346

    Article  PubMed  CAS  Google Scholar 

  9. Waldmann V, Deichmann M, Jackel A (2001) Disseminated melanoma cells in blood and bone marrow. Significance and detection by potential tumor markers. Hautarzt 52(4):298–303

    Article  PubMed  CAS  Google Scholar 

  10. Heiss MM, Simon EH, Beyer BC et al (2002) Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance ofurokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 20(8):2005–2016

    Article  PubMed  CAS  Google Scholar 

  11. Mansi JL., Easton D, Berger U et al (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up. Eur J Cancer 27:1552–1555

    Article  PubMed  CAS  Google Scholar 

  12. Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533

    Article  PubMed  CAS  Google Scholar 

  13. Solomayer EF, Diel IJ, Salanti G et al (2001) Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7:4102–4108

    PubMed  CAS  Google Scholar 

  14. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005 Aug 25, 353(8):793–802

    Google Scholar 

  15. Becker S, Becker-Pergola G, Fehm T, Emig R, Wallwiener D, Solomayer EF (2005) Image Analysis Systems for the detection of disseminated breast cancer cells on bone marrow cytospins. J Clin Lab Anal 19:115–119

    Article  PubMed  Google Scholar 

  16. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O et al (1999) Standardization of the immunological detection of cancer cells in bone marrow and blood: establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 5:377–388

    Article  Google Scholar 

  17. Smith IE, Lipton L (2001) Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2(9):561–570

    Article  PubMed  CAS  Google Scholar 

  18. Scholl SM, Beuzeboc P, Harris AL, Pierga JY, Asselain B, Palangie T, Dorval T, Jouve M, Dieras V, Pouillart P (1998) Is primary chemotherapy useful for all patients with primary invasive breast cancer ? Recent Res Cancer Res 152:217–226

    CAS  Google Scholar 

  19. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20(6):1456–1466

    Article  PubMed  CAS  Google Scholar 

  20. Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 16:557–566

    PubMed  CAS  Google Scholar 

  21. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533

    Article  PubMed  CAS  Google Scholar 

  22. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary breast cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197–202

    Article  PubMed  CAS  Google Scholar 

  23. Diel IJ, Kaufmann M, Solomayer E-F, Wallwiener D, Gollan C,Goerner R, Kaul S, Costa SD, von Minckwitz G, Holle R, Bastert R (1997) Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom. Geburtsh u Frauenheilk 57:333–341

    Article  Google Scholar 

  24. Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004) The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 10(9):3091–3097

    Article  PubMed  Google Scholar 

  25. Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T (2005) Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.Breast Cancer Res Treat 2005 Dec 1:1–6

    Google Scholar 

  26. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9(7):2598–2604

    PubMed  CAS  Google Scholar 

  27. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol Jan 18(1):80–86

    CAS  Google Scholar 

  28. Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC (2005) Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.Int J Cancer 2005 Mar 10, 114(1):94–100

    Google Scholar 

  29. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.Cancer. 2005 Mar 1, 103(5):884–891

    Google Scholar 

  30. Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N (2003) Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. Recent Res Cancer Res 162:89–100

    Google Scholar 

  31. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riehtmüller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424

    Article  PubMed  CAS  Google Scholar 

  32. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJF, Kaufmann M, Diebold J, Arnholdt H, Müller P, Bischoff J, Harich D, Schlimok G, Rietmüller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastases: genetic analyis of systemic breast cancer progression. PNAS 100:7737–7742

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Tübingen University Hospital, Calwerstr. 7, 72076, Tübingen, Germany

    Sven Becker, Erich Solomayer, Graziella Becker-Pergola, Diethelm Wallwiener & Tanja Fehm

Authors
  1. Sven Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erich Solomayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Graziella Becker-Pergola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Diethelm Wallwiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tanja Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Becker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, S., Solomayer, E., Becker-Pergola, G. et al. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106, 239–243 (2007). https://doi.org/10.1007/s10549-006-9484-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9484-5

Keywords

Search

Navigation